DISC MEDICINE INC

DISC Medicine insider sales: CEO’s 10‑b5‑1 trades show personal portfolio moves, not confidence loss, amid strong pipeline and rising stock price.

DISC Medicine’s COO’s recent insider buy signals confidence amid a 52‑week high, hinting the stock may be undervalued as the company pivots to medical‑device commercialization.

Inside DISC Medicine’s trading plan: Khara Rahul sells at $80, buys at $14.69, and keeps 57k shares—balancing liquidity, confidence, and future funding needs.

Disc Medicine insider trades show disciplined liquidity and long‑term growth confidence—executive buying and selling under Rule 10b5‑1 boosts investor trust and signals a strong future outlook.

Disc Medicine COO’s Rule 10b5‑1 trades reveal disciplined buying and selling—buy at $13.50, sell at $72.66—showing insider confidence in the company’s growth and upcoming clinical milestones.

Disc Medicine insiders buy shares at deep discounts and stack options, signaling confidence in its hematology pipeline, yet investors should watch clinical milestones before betting.